Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

What Was Tested

The trial (phase 2) is built around Semaglutide.

However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months.

This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow.

It had two arms (groups): Semaglutide (experimental) and No Intervention (no intervention).

Semaglutide.

No Intervention.

The registry classes the interventions as drug.

More on the Plan

The researchers are performing a pilot trial to obtain the factual feasibility prerequisites essential for the planning, design, funding and execution of a subsequent main phase trial.

Methods: Glucagon-like peptide-1 receptor agonists for Endovascular Stroke Thrombectomy (LEAST) is a multicentre, prospective, randomized, open label, blinded endpoint (PROBE) pilot clinical trial.

Outcomes: The primary feasibility endpoint is recruitment rate.

Secondary feasibility endpoints include retention rates and medication adherence.

Who Took Part

Enrollment: 100 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18 years or above on the date of randomization. Pre-stroke modified Rankin Scale (mRS) 0 or 1. Ability to randomize within 6 hours from the end of EVT. Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR).

The full record lists 6 inclusion and 13 exclusion criteria; among the exclusions: pregnancy or breast-feeding; cirrhosis or severe hepatic dysfunction, characterized by jaundice, encephalopathy or coagulopathy; history of pancreatitis in the year prior to randomization or evidence of acute pancreatitis on randomization.

How the Study Was Run

It was run as a randomized, parallel-group and single-blind study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Semaglutide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-10-31 with completion listed for 2028-10-31.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Feasibility - Recruitment (time frame: From site activation until the end of recruitment (approximately 24 months)).

It also tracked 2 secondary outcomes, for example Medication Adherence and Retention Rate.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 100 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.